Back to People

Alex Pasteur, Ph.D.

Partner

About

Alex Pasteur is a Partner with F-Prime Capital based in London.  He has worked in healthcare investing since 2001. Alex focuses on investments in therapeutics and healthcare IT.  His portfolio includes/included  Acacia Pharma (BRU: ACPH), Adaptimmune Therapeutics (NASDAQ: ADAP) Therapeutics Ltd, (acquired by Angelini Pharma), Castor (Ciwit BV), Genomics PLC, Orchard Therapeutics (NASDAQ: ORTX), Oviva AG, Owkin Inc., Peptone, Pulmocide Ltd., and Shift Bioscience.  Prior to joining F-Prime in 2012, Alex worked at MVM Life Science Partners LLP in the USA and Europe.

Alex earned a M.A. in Natural Sciences from Cambridge University and a Ph.D. in Chemistry from Cambridge University.

  • Acacia Pharma (EURONEXT:ACPH) is a commercially driven hospital pharmaceutical group focused on the development and commercialisation of new nausea and vomiting treatments for surgical and cancer patients. Acacia was acquired by Eagle Pharmaceuticals in 2022.

    • Category

      • Therapeutics

    • Status

      • Acquired
      • Public

    • Location

      Cambridge, United Kingdom

    • Year Invested

      2013

    • Team

      Alex Pasteur, Ph.D.

  • Adaptimmune (NASDAQ: ADAP) is a cellular therapeutics company developing affinity enhanced T-cell receptor (TCR) engineered T-cells to treat solid tumor and hematological cancers. Learn more at www.adaptimmune.com.

  • Arvelle Therapeutics is a biopharmaceutical company with the mission of bringing innovative solutions to patients suffering from CNS disorders. Arvelle is responsible for the development and commercialization of cenobamate, an investigational antiepileptic drug, in the European market.  Arvelle Therapeutics was acquired by Angelini Pharma in January 2021.

    • Category

      • Therapeutics

    • Status

      • Acquired

    • Location

      Basel, Switzerland

    • Year Invested

      2019

    • Team

      Alex Pasteur, Ph.D.

  • Castor is a leading provider of decentralized and hybrid clinical trial solutions to democratize research. With the highest rated eClinical platform for decentralized and hybrid clinical trials, Castor’s plug and play platform offers rapid deployment at scale, enabling researchers to create a trial in a matter of clicks, with easy enrollment, consent and real-world data capture. Learn more at www.castoredc.com.

    • Category

      • Health IT/Services

    • Status

      • Private

    • Location

      Amsterdam, The Netherlands and Hoboken, NJ

    • Year Invested

      2021

    • Team

      Alex Pasteur, Ph.D.

  • Galatea Bio is a biobank intended to improve diagnostic testing and accelerate drug discovery in diverse underserved populations. The company functions as a biosample to bioinformatics platform for powering genomic discovery in understudied populations and identifies patients at risk of suffering severe multi-inflammatory syndromes or infections.  Learn more at www.galatea.bio.

    • Category

      • Therapeutics

    • Status

      • Private

    • Location

      Hialeah, FL

    • Year Invested

      2021

    • Team

      Alex Pasteur, Ph.D.

  • Genomics plc’s vision is to use genomic insights to transform the drug discovery industry by getting better drugs developed more quickly and targeted at the right group of patients. Learn more at https://www.genomicsplc.com

  • NodThera is a biotech engaged in innate immune/inflammasome research. Our leading project is focused on developing inhibitors of the NLRP3 inflammasome for the treatment of inflammatory and neuroinflammatory diseases. Learn more at www.nodthera.com

  • Orchard Therapeutics (NASDAQ:ORTX) Orchard Therapeutics is a fully integrated commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and life-threatening rare diseases through innovative gene therapies. Learn more at www.orchard-tx.com.

  • Oviva is a new type of healthcare provider using technology to scale the dietitian workforce to help meet the growing number of patients with diet-related health conditions. Learn more at www.oviva.com/uk/.

  • Owkin combines life-science and machine learning expertise to make drug development and clinical trial design more targeted and more cost effective. Owkin’s machine learning algorithms create models that predict disease evolution and treatment outcomes. These predictive models are implemented in clinical trials for enhanced analysis, surrogate endpoints, patient stratification, patient selection, and high-value subgroup identification. The impact of this research is faster discovery of better treatments at a lower cost. Learn more at www.owkin.com.

    • Category

      • Health IT/Services

    • Status

      • Private

    • Location

      New York, NY

    • Year Invested

      2019

    • Team

      Alex Pasteur, Ph.D.

  • Peptone is an innovative drug discovery company applying advanced biophysics, atomic-level experimental approaches, cutting-edge supercomputing and machine learning to the challenge of biopharmaceutical research and development. By bringing these proprietary approaches together, we are exploring the world of intrinsically disordered proteins (IDPs) – proteins without a fixed structure that play a significant role in health and disease – opening up the possibility of novel therapeutics against an entire class of high value and previously undruggable targets. Learn more at peptone.io.

  • Pulmocide is a biopharmaceutical company with a mission to treat common acute and chronic respiratory tract infections associated with serious complications and devastating effects on patients’ quality of life. Learn more at www.pulmocide.com.